Download PDF

1. Company Snapshot

1.a. Company Description

Medartis Holding AG, a medical device company, develops, manufactures, and sells implant solutions worldwide.Its medical devices are used for the treatment of surgical fixation of bone fractures for upper and lower extremities, as well as for the cranio-maxillofacial surgery.The company offers osteosynthesis instruments for the areas of the hand, wrist, elbow, shoulder, and foot and ankle, as well as for the areas of the mandible, midface, orthognathic, and cranium under the APTUS and MODUS names.


The company serves the surgeons, hospitals, and medical centers, as well as group purchasing organizations.Medartis Holding AG was founded in 1997 and is headquartered in Basel, Switzerland.

Show Full description

1.b. Last Insights on MED

Medartis Holding AG faced negative drivers, including a 7.7% reduction in holdings value by significant shareholder Thomas Straumann. This decrease in insider holdings may signal concerns about the company's growth prospects. Additionally, the fair value estimate of CHF 78.35, calculated using the 2 Stage Free Cash Flow to Equity, may not be met if the company fails to execute on its expansion plans. Recent earnings releases have not provided a positive catalyst, and investors may be cautious about the company's short-term outlook.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Calculating The Fair Value Of Medartis Holding AG (VTX:MED)

Oct -28

Source:

Card image cap

Medartis Holding AG (VTX:MED) Top Key Executive Thomas Straumann, the company's largest shareholder sees 7.7%reduction in holdings value

Sep -26

Source:

Card image cap

Medartis Holding First Half 2025 Earnings: CHF0.12 loss per share (vs CHF0.21 profit in 1H 2024)

Aug -24

Source:

Card image cap

At CHF84.40, Is It Time To Put Medartis Holding AG (VTX:MED) On Your Watch List?

Aug -21

Source:

Card image cap

Medartis Holding AG (XSWX:MED) (Q2 2025) Earnings Call Highlights: Strong Revenue Growth and ...

Aug -20

Source:

Card image cap

Medartis Holding AG (XSWX:MED) (Q4 2024) Earnings Call Highlights: Strong Revenue Growth and ...

Mar -19

Source:

Card image cap

Bell Food Group's (VTX:BELL) Returns Have Hit A Wall

Jan -19

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (13.62%)

6. Segments

Upper Extremities

Expected Growth: 15%

Upper Extremities from Medartis Holding AG's 15% growth driven by increasing demand for minimally invasive surgeries, advancements in implant technologies, and expanding presence in emerging markets. Additionally, rising incidence of osteoporosis and sports-related injuries contribute to the growth, as well as the company's strategic partnerships and investments in R&D.

Cranio-Maxillofacial (CMF) and Others

Expected Growth: 12%

Cranio-Maxillofacial (CMF) growth driven by increasing demand for orthognathic and reconstructive surgeries, fueled by rising awareness of facial aesthetics and trauma cases. Others segment growth attributed to expanding product portfolio and strategic partnerships, enhancing market presence and customer reach.

Lower Extremities

Expected Growth: 10%

The 10% growth in Lower Extremities from Medartis Holding AG is driven by increasing demand for minimally invasive surgical procedures, advancements in implant technologies, and a growing elderly population requiring orthopedic interventions. Additionally, strategic partnerships and expanding distribution networks contribute to the segment's growth.

7. Detailed Products

Aptus Spine

Aptus Spine is a comprehensive range of spinal implants and instruments designed for various spinal procedures.

Aptus Trauma

Aptus Trauma is a range of implants and instruments designed for treating orthopedic trauma injuries.

Aptus CMF

Aptus CMF is a range of implants and instruments designed for cranio-maxillofacial surgery.

Aptus Veterinary

Aptus Veterinary is a range of implants and instruments designed for veterinary orthopedic surgery.

8. Medartis Holding AG's Porter Forces

Forces Ranking

Threat Of Substitutes

Medartis Holding AG's products are specialized and have a high barrier to entry, making it difficult for substitutes to enter the market.

Bargaining Power Of Customers

Medartis Holding AG's customers are mainly hospitals and medical professionals, who have limited bargaining power due to the specialized nature of the products.

Bargaining Power Of Suppliers

Medartis Holding AG's suppliers are mainly raw material providers, who have some bargaining power due to the high demand for their products.

Threat Of New Entrants

Medartis Holding AG operates in a highly regulated industry, making it difficult for new entrants to enter the market.

Intensity Of Rivalry

Medartis Holding AG operates in a highly competitive market with several established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 7.79%
Debt Cost 8.14%
Equity Weight 92.21%
Equity Cost 8.88%
WACC 8.82%
Leverage 8.45%

11. Quality Control: Medartis Holding AG passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Medartis

A-Score: 3.9/10

Value: 3.0

Growth: 5.0

Quality: 4.5

Yield: 0.0

Momentum: 8.5

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Ion Beam Applications

A-Score: 3.7/10

Value: 6.3

Growth: 4.1

Quality: 4.1

Yield: 2.5

Momentum: 1.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
IceCure Medical

A-Score: 3.6/10

Value: 6.0

Growth: 2.8

Quality: 3.4

Yield: 0.0

Momentum: 9.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Stratec

A-Score: 3.0/10

Value: 5.4

Growth: 3.4

Quality: 4.4

Yield: 3.1

Momentum: 0.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
InspireMD

A-Score: 2.9/10

Value: 6.2

Growth: 4.2

Quality: 3.9

Yield: 0.0

Momentum: 2.5

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Bactiguard Holding

A-Score: 2.0/10

Value: 4.0

Growth: 4.8

Quality: 3.0

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

91.1$

Current Price

91.1$

Potential

-0.00%

Expected Cash-Flows